Adagio Therapeutics focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
